MX2022006031A - Métodos de tratamiento del cáncer con inhibidores de dkk-1. - Google Patents

Métodos de tratamiento del cáncer con inhibidores de dkk-1.

Info

Publication number
MX2022006031A
MX2022006031A MX2022006031A MX2022006031A MX2022006031A MX 2022006031 A MX2022006031 A MX 2022006031A MX 2022006031 A MX2022006031 A MX 2022006031A MX 2022006031 A MX2022006031 A MX 2022006031A MX 2022006031 A MX2022006031 A MX 2022006031A
Authority
MX
Mexico
Prior art keywords
cancer
dkk
inhibitors
methods
treating cancer
Prior art date
Application number
MX2022006031A
Other languages
English (en)
Inventor
Michael H Kagey
Girish Somala Naik
Cynthia A Sirard
Original Assignee
Leap Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leap Therapeutics Inc filed Critical Leap Therapeutics Inc
Publication of MX2022006031A publication Critical patent/MX2022006031A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un método para tratar a un sujeto que sufre de un cáncer, que comprende los pasos de obtener una muestra de una célula de cáncer del sujeto; determinar una secuencia de una proteína de subunidad catalítica de 3 - quinasa de fosfatidilinositol (PIK3CA) En la muestra; y administrar una primera cantidad de un inhibidor de DKK1 al sujeto determinado para tener la secuencia de proteína PIK3CA que Incluye una mutación de activación. El cáncer es un cáncer de endometrio epitelial o un cáncer de ovario epitelial.
MX2022006031A 2019-11-22 2020-11-23 Métodos de tratamiento del cáncer con inhibidores de dkk-1. MX2022006031A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962939174P 2019-11-22 2019-11-22
PCT/US2020/061773 WO2021102403A1 (en) 2019-11-22 2020-11-23 Methods of treating cancer using dkk-1-inhibitors

Publications (1)

Publication Number Publication Date
MX2022006031A true MX2022006031A (es) 2022-07-19

Family

ID=73834617

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006031A MX2022006031A (es) 2019-11-22 2020-11-23 Métodos de tratamiento del cáncer con inhibidores de dkk-1.

Country Status (11)

Country Link
US (1) US20240141023A1 (es)
EP (1) EP4061419A1 (es)
JP (1) JP2023502666A (es)
KR (1) KR20220131223A (es)
CN (1) CN114929275A (es)
AU (1) AU2020386091A1 (es)
BR (1) BR112022009708A2 (es)
CA (1) CA3158661A1 (es)
IL (1) IL293090A (es)
MX (1) MX2022006031A (es)
WO (1) WO2021102403A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024015463A1 (en) * 2022-07-12 2024-01-18 Leap Therapeutics, Inc. Combination therapy

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5475120A (en) 1990-11-02 1995-12-12 University Of Florida Method for the isolation and purification of taxol and its natural analogues
US5194635A (en) 1991-03-18 1993-03-16 Virginia Tech Intellectual Properties, Inc. Rearranged taxol compounds and method of using in testing of in vivo activity
US5488116A (en) 1992-03-30 1996-01-30 Sloan-Kettering Institute For Cancer Research Total synthesis of taxol and analogues thereof
US5416225A (en) 1992-03-30 1995-05-16 Sloan-Kettering Institute For Cancer Research Total synthesis of taxol
US5440056A (en) 1992-04-17 1995-08-08 Abbott Laboratories 9-deoxotaxane compounds
EP0639186B1 (en) 1992-04-17 1999-06-23 Abbott Laboratories Taxol derivatives
US5461169A (en) 1992-06-23 1995-10-24 The Scripps Research Institute Total synthesis of taxol and taxol analogs
US5440057A (en) 1993-08-20 1995-08-08 The Scripps Research Institute Access to taxol analogs
WO1994005282A1 (en) 1992-09-04 1994-03-17 The Scripps Research Institute Water soluble taxol derivatives
US5478854A (en) 1992-10-01 1995-12-26 Bristol-Myers Squibb Company Deoxy taxols
US5411984A (en) 1992-10-16 1995-05-02 Virginia Tech Intellectual Properties, Inc. Water soluble analogs and prodrugs of taxol
EP0627010A4 (en) 1992-12-07 1995-05-03 Univ Michigan PROCESS FOR ISOLATION AND PURIFICATION OF TAXOL AND TAXANES FROM -i (TAXUS) spp.
US5468769A (en) 1993-07-15 1995-11-21 Abbott Laboratories Paclitaxel derivatives
FR2707642B1 (fr) 1993-07-16 1995-10-13 Electricite De France Dérivés de polyéthers et d'hétérocycles pentacycliques, leurs polymères et leurs applications, notamment à la complexation d'ions métalliques.
US5405972A (en) 1993-07-20 1995-04-11 Florida State University Synthetic process for the preparation of taxol and other tricyclic and tetracyclic taxanes
US5565478A (en) 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
US5508447A (en) 1994-05-24 1996-04-16 Board Of Regents, The University Of Texas System Short synthetic route to taxol and taxol derivatives
US5489589A (en) 1994-12-07 1996-02-06 Bristol-Myers Squibb Company Amino acid derivatives of paclitaxel
US7446181B2 (en) 1998-01-15 2008-11-04 Millennium Pharmaceuticals, Inc. Antibodies that bind human Dickkopf-1 proteins
AR075989A1 (es) * 2009-04-10 2011-05-11 Lilly Co Eli Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria
EP2542893A2 (en) * 2010-03-03 2013-01-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP3532099A1 (en) * 2016-10-26 2019-09-04 Leap Therapeutics, Inc. Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody

Also Published As

Publication number Publication date
EP4061419A1 (en) 2022-09-28
KR20220131223A (ko) 2022-09-27
BR112022009708A2 (pt) 2022-08-09
CN114929275A (zh) 2022-08-19
US20240141023A1 (en) 2024-05-02
CA3158661A1 (en) 2021-05-27
AU2020386091A1 (en) 2022-06-09
IL293090A (en) 2022-07-01
JP2023502666A (ja) 2023-01-25
WO2021102403A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
Li et al. Interleukin 17A promotes hepatocellular carcinoma metastasis via NF-kB induced matrix metalloproteinases 2 and 9 expression
MX2017014736A (es) Metodos terapeuticos y diagnosticos para cancer.
MX2018008421A (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
MX2015011362A (es) Metodo para el pronostico y tratamiento de metastasis de cancer.
SG11202012585YA (en) Hydroxymethylation analysis of cell-free nucleic acid samples for assigning tissue of origin, and related methods of use
MY192493A (en) Urinalysis device and dry reagent for quantitative urinalysis
MX2020009037A (es) Anticuerpos de b7-h4 y métodos para usarlos.
NZ629074A (en) Biomarkers for gastric cancer and uses thereof
WO2006113493A3 (en) Methods of determining cancer prognosis via natural killer cell activity
MA38828A1 (fr) Anticorps dirigés contre l'inhibiteur des activateurs du plasminogène de type 1 (pai-1) et leurs utilisations
MX2019008911A (es) Metodos, matrices y usos de estos.
MX2020010387A (es) Metodos para detectar y cuantificar fgf21.
AU2018338322A1 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
CR20220646A (es) Anticuerpos contra el sars-cov-2 y métodos de selección y uso de los mismos
MX2022006031A (es) Métodos de tratamiento del cáncer con inhibidores de dkk-1.
AU2018286823A1 (en) Compressible extraction instrument for pretreating a sample
Tahir et al. Serum caveolin-1, a biomarker of drug response and therapeutic target in prostate cancer models
WO2022119830A8 (en) Methods and compositions for neoadjuvant and adjuvant urothelial carcinoma therapy
MX2022004688A (es) Métodos para tratar un cáncer hematológico y uso de biomarcadores compañeros para 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-mor folinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona.
Garamszegi et al. Extracellular matrix-induced gene expression in human breast cancer cells
MX2022000848A (es) Composiciones amortiguadoras para reducir la agregacion.
MX2018015140A (es) Firmas de biomarcadores de lupus eritematoso sistemico y sus usos.
Wang et al. Upregulation of proline rich 11 is an independent unfavorable prognostic factor for survival of tongue squamous cell carcinoma patients
WO2018208749A8 (en) PROSTATE CANCER GENE PROFILES AND THEIR METHODS OF USE
WO2017211893A8 (en) Biomarker signatures of systemic lupus erythematosus and uses thereof